| Source publication date | (updated; first published 2026-02-20) |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | 1st Optimal |
| URL | 1stoptimal.com/testosterone-replacement-therapy-for-men-complete-guide-2026-update (opens in a new tab) |
Specific claim evaluated
Most risks of testosterone therapy come from poor management, not the therapy itself.
Primary research supporting or contradicting the claim
In TRAVERSE, a monitored randomized trial using transdermal testosterone in men with confirmed hypogonadism, atrial fibrillation, acute kidney injury and pulmonary embolism were more frequent with testosterone than placebo (Lincoff et al., 2023), and clinical fractures were more frequent (Snyder et al., 2024).
Corrected evidence-based interpretation
Monitoring reduces some risks such as erythrocytosis, but adverse events including atrial fibrillation, pulmonary embolism and fractures occurred under trial monitoring and are attributable to testosterone itself.
Rationale for grade
The page gives no evidence for its statement, and the largest monitored randomized trial contradicts it. The page also names no specific adverse events, so readers receive no account of the risks it dismisses.
References
- Lincoff AM, Bhasin S, Flevaris P, Mitchell LM, Basaria S, Boden WE, Cunningham GR, Granger CB, Khera M, Thompson IM, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023;389(2):107-117. PMID
Supporting excerpt: "noninferior to placebo with respect to the incidence of major adverse cardiac events" - Snyder PJ, Bauer DC, Ellenberg SS, Cauley JA, Buhr KA, Bhasin S, Miller MG, Khan NS, Li X, Nissen SE. Testosterone treatment and fractures in men with hypogonadism. N Engl J Med. 2024;390(3):203-211. PMID
Supporting excerpt: "testosterone treatment did not result in a lower incidence of clinical fracture than placebo"